ImmunityBio (NASDAQ:IBRX) Shares Gap Up - Still a Buy?

Key Points

• Financing boost: ImmunityBio secured $75 million of non‑dilutive financing under its Royalty Interest Purchase Agreement and completed $100 million of financing transactions, bringing committed capital to $375 million to support global expansion and its immunotherapy pipeline.
• Regulatory and legal risk: An FDA warning about unsupported cancer‑treatment claims tied to the company’s executive chairman triggered sharp market repricing, a multibillion‑dollar market‑cap decline and a wave of securities class‑action filings.
• Mixed market view but overall upbeat analyst tone: Despite recent volatility and insider selling, analysts have an average "Moderate Buy" rating with a consensus target of $14.40, and the stock recently gapped up to roughly $7.27 (market cap about $7.37B).

Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $6.66, but opened at $7.15. ImmunityBio shares last traded at $7.2730, with a volume of 4,053,744 shares trading hands.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Raised additional liquidity — ImmunityBio secured $75 million of non‑dilutive financing under its Royalty Interest Purchase Agreement (bringing committed capital to $375M) and completed $100M of financing transactions to support global expansion and its immunotherapy pipeline; terms include a modest increase in royalty payback but maintain the royalty cap. ImmunityBio Strengthens Balance Sheet
• Negative Sentiment: FDA warning and market impact — Hagens Berman highlights that an FDA warning about unsupported cancer‑treatment claims tied to statements by the company’s executive chairman led to sharp market repricing (the firm cites a multibillion‑dollar market cap decline) and is the basis for a securities class action. This FDA notice is the proximate cause of the legal and investor backlash. Hagens Berman — FDA warning & class action
• Negative Sentiment: Wave of class‑action filings and investigations — multiple national plaintiff firms (including Kahn Swick & Foti, Glancy Prongay Wolke & Rotter, Rosen Law Firm, Bragar Eagel & Squire, Robbins LLP, RGRD Law, Block & Leviton and others) have filed or announced investigations, soliciting lead‑plaintiff applications and reminding investors of a May 26 deadline. The proliferation of filings increases potential legal costs, management distraction, and uncertain financial exposure. Representative notices: Kahn Swick & Foti notice Glancy Prongay notice Gross Law Firm notice

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on IBRX shares. Weiss Ratings reissued a "sell (e+)" rating on shares of ImmunityBio in a research report on Monday, December 29th. D. Boral Capital reiterated a "buy" rating and issued a $23.00 price target on shares of ImmunityBio in a report on Monday, March 23rd. Jefferies Financial Group raised their price objective on ImmunityBio from $8.00 to $9.00 and gave the stock a "buy" rating in a report on Friday, December 12th. HC Wainwright upped their target price on ImmunityBio from $10.00 to $15.00 and gave the company a "buy" rating in a research note on Monday, February 23rd. Finally, Piper Sandler reissued an "overweight" rating and issued a $12.00 price target (up from $7.00) on shares of ImmunityBio in a research note on Wednesday, March 4th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $14.40.

ImmunityBio Stock Performance

The company has a market capitalization of $7.37 billion, a PE ratio of -19.04 and a beta of -0.04. The business has a fifty day moving average price of $7.70 and a 200 day moving average price of $4.27.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million for the quarter. Research analysts forecast that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Christobel Selecky sold 25,000 shares of the stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total value of $250,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Barry J. Simon sold 75,000 shares of the business's stock in a transaction dated Tuesday, February 24th. The stock was sold at an average price of $12.01, for a total value of $900,750.00. Following the transaction, the director owned 2,850,821 shares in the company, valued at approximately $34,238,360.21. This represents a 2.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 501,967 shares of company stock valued at $4,466,412. 69.48% of the stock is owned by corporate insiders.

Institutional Trading of ImmunityBio

Several large investors have recently bought and sold shares of IBRX. Vanguard Group Inc. lifted its position in shares of ImmunityBio by 18.5% during the fourth quarter. Vanguard Group Inc. now owns 32,777,257 shares of the company's stock worth $64,899,000 after purchasing an additional 5,122,052 shares in the last quarter. State Street Corp grew its holdings in ImmunityBio by 45.4% during the 4th quarter. State Street Corp now owns 16,455,703 shares of the company's stock valued at $32,582,000 after purchasing an additional 5,139,890 shares in the last quarter. Geode Capital Management LLC increased its stake in ImmunityBio by 15.0% during the 4th quarter. Geode Capital Management LLC now owns 7,920,178 shares of the company's stock worth $15,684,000 after buying an additional 1,030,113 shares during the period. Armistice Capital LLC purchased a new stake in ImmunityBio during the 2nd quarter worth $20,497,000. Finally, Heights Capital Management Inc. acquired a new position in ImmunityBio in the 3rd quarter worth $16,152,000. Institutional investors and hedge funds own 8.58% of the company's stock.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.